Compare Financial Select Sector SPDR Fund (XLF) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Financial Select Sector SPDR Fund vs Zimmer Biomet Holdings Inc — how do they compare? Financial Select Sector SPDR Fund trades at $54.73 (market cap $50.06B), while Zimmer Biomet Holdings Inc trades at $89.91 (market cap $16.95B). The key difference: Financial Select Sector SPDR Fund is far larger — about 3× Zimmer Biomet Holdings Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Financial Select Sector SPDR Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Financial Select Sector SPDR Fund for 104 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| XLF | ZBH | |
|---|---|---|
Market Cap | $50.06B | $16.95B |
Volume | 47,464,120 | 2,505,240 |
52-Week High | $58.55 | $103.98 |
52-Week Low | $47.80 | $79.58 |
Typical Hold Time | 104 Days | 89 Days |
Sector | — | Health |
Enterprise Value | — | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
XLF trades at $54.73, up 1.82% with a bearish technical signal as moving averages and ADX indicators suggest selling pressure. The financial ETF faces sector headwinds with bank stocks lagging the S&P 500 by the widest margin since 1990 despite rising profits. Recent Fed stress test changes and interest rate hikes create both opportunities and challenges for financial sector performance.
Financial sector exposure benefits from rising interest rates but faces regulatory uncertainty and market underperformance risks. The ETF's concentrated 76-holding portfolio offers targeted financial exposure while competing with broader alternatives. Sector rotation into financials by fund managers in Q2 2026 suggests institutional confidence despite recent relative weakness.
Zimmer Biomet (ZBH) trades at $89.14, up 0.73% today, with a bearish technical signal but strong recent earnings beats. The stock shows robust fundamentals with a 69.87% gross margin and 2025 revenue of $8.23B, though net income margin has declined from 2023 peaks. Analyst consensus is a Buy with a $103.11 target, indicating potential upside, supported by a steady dividend and institutional accumulation.
The outlook is mixed: valuation metrics like a P/E of 21.57 appear reasonable, and earnings momentum is positive, but technical weakness and rising debt-to-asset ratios pose risks. Investment appeal hinges on execution of commercial transformations and procedure volume recovery, balancing growth prospects against competitive and operational headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Financial Select Sector SPDR Fund
The fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: diversified financial services; insurance; banks; capital markets; mortgage real estate investment trusts; consumer finance; thrifts; and mortgage finance. The fund is non-diversified.
Read more on XLF →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
